Australian Industry Concerned Over Comparator Drug, Differing Evidence Levels, As New PBS Guidance Draws Near
Executive Summary
The revised guidelines for making submissions to list drugs on the Australian Pharmaceutical Benefits Scheme have raised industry and patient concerns over the criteria for choosing the comparator drug, how to assess differing levels of evidence, and the need for more patient and clinician input.
You may also be interested in...
Australia Consults On New Guidelines For Reimbursement Listing
Clearer guidance for pharmaceutical companies on how to apply for a reimbursement listing for new drugs has moved a step nearer after the Australian government released the draft revised Pharmaceutical Benefits Advisory Committee (PBAC) guidelines1 for comment by April 5, 2016.
Stakeholders Urge Major Changes To Australia's PBS Listing Guidelines
The future shape of Australia's system for listing medicines on the Pharmaceutical Benefits Scheme is becoming clearer after the government published stakeholder responses to a consultation on the long-awaited review of the Pharmaceutical Benefits Advisory Committee guidelines, which are used by the pharmaceutical industry to prepare requests for PBS listing1,2.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.